Indeed, there is wide evidence that the use of GLP-1 RAs in T2DM patients is associated with a lower incidence of depression and anxiety compared to controls treated with different therapies [23, 48, 49]. The gene discussed is GLP1R; the disease is depressive symptom measurement.